IL33 and colorectal carcinoma: IL-33 can alter the TME by recruiting CD11b+GR1+, CD11b+F4/80+myeloid cells and macrophages 7, 36, activating subepithelial myofibroblasts (SEMFs) and mast cells 37, and altering the phenotype of Tregs 11, thus promoting the progression of CRC.